Skip to Content

Rimegepant Bests Placebo for Preventing Migraine

MONDAY, Dec. 21, 2020 -- Taken every other day, rimegepant demonstrates efficacy for the preventive treatment of migraine, according to a study published online Dec. 15 in The Lancet.

Robert Croop, M.D., from Biohaven Pharmaceuticals in New Haven, Connecticut, and colleagues compared the efficacy of rimegepant with placebo for preventive treatment of migraine. Participants at 92 sites were randomly assigned to either oral rimegepant (348 patients) or placebo (347 patients) every other day for 12 weeks.

The researchers found that rimegepant was superior to placebo on the change in the mean number of migraine days per month during weeks 9 to 12, with a decrease in mean number of migraine days per month of 4.3 days with rimegepant and 3.5 days with placebo. More than one-third (36 percent) of patients who received rimegepant reported an adverse event, as did 36 percent of those who received placebo. Discontinuation due to an adverse event occurred in seven participants receiving rimegepant and four receiving placebo.

"The short half-life of rimegepant relative to monoclonal antibodies is especially useful for patients who have a planned or unplanned pregnancy or adverse events that might require rapid cessation of drug exposure," the authors write. "Additional research could help to clarify the role of rimegepant for contemporaneous preventive and acute treatment of migraine."

Several authors disclosed financial ties to pharmaceutical companies, including Biohaven, which manufactures rimegepant and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: December 2020

Read this next

Cases of Idiopathic Intracranial HTN on the Rise in Wales

FRIDAY, Jan. 22, 2021 -- The incidence and prevalence of idiopathic intracranial hypertension are increasing in Wales, corresponding to increasing body mass index (BMI) in the...

Mindfulness Training Does Not Reduce Migraine Frequency

WEDNESDAY, Jan. 6, 2021 -- Mindfulness-based stress reduction (MBSR) does not improve migraine frequency more than headache education, according to a study published online Dec....

Higher Odds of Migraines Seen Among Sexual Minorities

TUESDAY, Sept. 29, 2020 -- Migraine is more common among sexual-minority groups than individuals identifying as exclusively heterosexual, according to a research letter published...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.